Mirikizumab
Mirikizumab is a pharmaceutical drug with 27 clinical trials. Currently 11 active trials ongoing. Historical success rate of 92.9%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
6
Mid Stage
16
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
92.9%
13 of 14 finished
7.1%
1 ended early
11
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Clinical Trials (27)
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
A Study of Mirikizumab in Participants With Plaque Psoriasis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27